Fighting Antimicrobial Resistance:
from the
Biological EmergencY to Opportunistic and Neglected Diseases
« Usually in movies, an alien lands in a new city (usually San Francisco for any reason) and, despite the efforts of hundreds of soldiers from the best army on the planet, it escapes every bullet we fire against it… Then, we need to change the nature of our weapons, to create something new to face it and make the city free again…
Just like those aliens, some bacteria can get away from most of the treatments we have in hospitals… That’s why we must go FAR BEYOND… It is too late for the next steps, it is time for new ways to face them, it is time for a new generation of antibiotics…
DimiCare has identified and characterized thanks to ARROW, our screening platform, a new class of precision antibiotics, a “magic bullet” which eliminates 100% of targeted multidrug-resistant bacteria, without any resistance to, later be degraded by the organism without any environmental impact.»
Our screening Antimicrobial Research and Optimization Workflow (ARROW) platform allowed us to discover highly specific compounds against emergent and public health priority pathogens.
Updated clinical strains
We have hundreds of clinical strains recently isolated from patients to test the bioactivity of our compounds against current strains in hospitals.
New class compounds bank
Our Medicinal Chemistry experts work hard to feed our growing in-house bank of synthetic bioactive compounds
Regenerative AI boosted research
Our team are implementing AI tools to improve and accelerate drug discovery and development - in silico modelling, preliminary PK/PD results, SAR analysis...
Research-Discover-Valorize
Fundamental research is on our DNA, and the basis of reliable results are innovative but standardized methods, reason why we work on new methodologies to characterize the bioactivity of our compounds faster and easier.
Dimicare Biotech is a spin-off from University Côte d'Azur (UniCA) focused on the development of a new generation of drugs against difficult-to-treat infections. We devep precision antibiotics with a high and specific efficacy, reduced resistant rate (<10e-10) and undetectable ecological impact( no effect on microorganisms after degradation)...
Currently, our main project (DCB001) focuses on the development of a new precision treatment against MDR (multidrug-resistant) S. aureus strains (including the WHO priority MRSA; methicillin-resistance S. aureus).
DimiCare is building a great team involving academic researchers, infectiology and microbiology medical doctors, and strategic development experts, assuring a solid growth not only in the scientific but also in the business field.
Juan A. Garcia-Sanchez
PhD
CEO/CSO
Pauline Meola
MSc
CTO
Laurent Boyer
PhD
Head of Biology
Cyril Ronco
PhD
Head of Chemistry
Patrick Munro
PhD
Senior Microbiologist
Grégory Michel
PhD
Senior Microbiologist
O.D.
PhD
Business Developer
Christelle Pomares-Estran
MD, PhD
Clinical Parasitology Advisor
Raymond Ruimy
MD, PhD
Clinical Bacteriology Advisor
Johan Courjon
MD, PhD
Clinical Infectiology Advisor
Rachid Behinda
PhD
Medicinal Chemistry Advisor
DimiCare is promoting its new candidat and communicating about AMR therapies everytime! Get updated about the news concerning our technology and dream team!
Are you interested on our project?
Here are the different ways to contact us!
Legal Notice © Copyright. All rights reserved.
Nous avons besoin de votre consentement pour charger les traductions
Nous utilisons un service tiers pour traduire le contenu du site web qui peut collecter des données sur votre activité. Veuillez consulter les détails dans la politique de confidentialité et accepter le service pour voir les traductions.